[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100593757":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":34,"centralContacts":38,"locations":48,"responsibleParty":214,"collaborators":218,"id":222,"slug":223,"hasResults":224,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":224,"sex":230,"minAge":231,"maxAge":232,"enrollmentInfo":233,"targetDuration":12,"studyType":236,"phases":237,"briefSummary":239,"conditions":240,"keywords":244,"overallStatus":248,"whyStopped":12,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":258},{"fullName":5,"class":6},"Peking University People's Hospital","OTHER",[8,13,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Control group","NO_INTERVENTION","After being enrolled, the participants will undergo a liver US examination and a serum AFP test every six months. For those participants who are suspected HCC, an enhanced abdominal CT or enhanced MRI will be performed for confirmation. If the imaging suggests HCC, the research subject will be removed from the group and enter the clinical routine diagnosis and treatment process. If there is no evidence of HCC, the subject will continue to be followed up as planned. Finally, at the end of the 18-month follow-up period, a routine enhanced abdominal CT\u002FMRI will be carried out to confirm the presence of HCC. After the completion of 18 months surveillance, researchers will continue long-term follow-up for another 24 months.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Non-contrast abbreviated MRI group","EXPERIMENTAL","After the participants are enrolled, a serum AFP test and a NC-AMRI examination including T2-weighted imaging (T2WI) and diffusion-weighted imaging (DWI) will be conducted at the 6th month. A liver US examination and a serum AFP test will be carried out at the 12th month. A serum AFP test and a NC-AMRI examination will be performed at the 18th month. For those participants who are suspected HCC, an enhanced abdominal CT or enhanced MRI will be performed for confirmation. If the imaging suggests HCC, the research subject will be removed from the group and enter the clinical routine diagnosis and treatment process. If there is no evidence of HCC, the subject will continue to be followed up as planned. Finally, at the end of the 18-month follow-up period, a routine enhanced abdominal CT\u002FMRI will be carried out to confirm the presence of HCC. After the completion of 18 months surveillance, researchers will continue long-term follow-up for another 24 months.",[18],"Device: non-contrast abbreviated MRI (NC-AMRI)",{"label":20,"type":15,"description":21,"interventionNames":22},"Enhanced abbreviated MRI group","After the participants are enrolled, a serum AFP test and a E-AMRI examination (using gadoxetic acid disodium) including T2WI, DWI and hepatobiliary phase (HBP) images will be conducted at the 6th month. A liver US examination and a AFP test will be carried out at the 12th month. A serum AFP test and a E-AMRI examination will be performed at the 18th month. For those participants who are suspected HCC, an enhanced abdominal CT or enhanced MRI will be performed for confirmation. If the imaging suggests HCC, the research subject will be removed from the group and enter the clinical routine diagnosis and treatment process. If there is no evidence of HCC, the subject will continue to be followed up as planned. Finally, at the end of the 18-month follow-up period, a routine enhanced abdominal CT\u002FMRI will be carried out to confirm the presence of HCC. After the completion of 18 months surveillance, researchers will continue",[23],"Device: enhanced abbreviated MRI (E-AMRI)",[25,30],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":12},"DEVICE","non-contrast abbreviated MRI (NC-AMRI)","Non-contrast abbreviated MRI (NC-AMRI) examination include T2-weighted imaging (T2WI) and diffusion-weighted imaging (DWI), which takes 10 minutes approximately.",[14],{"type":26,"name":31,"description":32,"armGroupLabels":33,"otherNames":12},"enhanced abbreviated MRI (E-AMRI)","E-AMRI examination (using gadoxetic acid disodium) including T2-weighted imaging (T2WI) and diffusion-weighted imaging (DWI)and hepatobiliary phase (HBP) images, which takes 15 minutes approximately.",[20],[35],{"name":36,"affiliation":5,"role":37},"Yi Wang, Professor","STUDY_CHAIR",[39,44],{"name":40,"role":41,"phone":42,"phoneExt":12,"email":43},"Yi Wang, MD","CONTACT","86-010-88325193","wang_yi@hsc.pku.edu.cn",{"name":45,"role":41,"phone":46,"phoneExt":12,"email":47},"Rong Liu, MD","86-015210594133","lrr19910222@163.com",[49,65,79,93,107,121,135,145,159,172,186,200],{"facility":5,"status":12,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Beijing","Beijing Municipality","100081","China","CN",{"type":56,"coordinates":57},"Point",[58,59],116.39723,39.9075,{"lat":59,"lon":58},[62],{"name":63,"role":41,"phone":64,"phoneExt":12,"email":43},"YI WANG, MD","86-010-88325811",{"facility":66,"status":12,"city":67,"state":68,"zip":12,"country":53,"countryCode":54,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"The First Affiliated Hospital of Army Medical University","Chongqing","Chongqing Municipality",{"type":56,"coordinates":70},[71,72],106.55771,29.56026,{"lat":72,"lon":71},[75],{"name":76,"role":41,"phone":77,"phoneExt":12,"email":78},"Ping Cai, MD","86-013228683331","530305942@qq.com",{"facility":80,"status":12,"city":81,"state":82,"zip":12,"country":53,"countryCode":54,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"Handan Central Hospital","Handan","Hebei",{"type":56,"coordinates":84},[85,86],114.48764,36.60999,{"lat":86,"lon":85},[89],{"name":90,"role":41,"phone":91,"phoneExt":12,"email":92},"Shifeng Xiang, MD","86-0310-2112789","xsf@live.cn",{"facility":94,"status":12,"city":95,"state":96,"zip":12,"country":53,"countryCode":54,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"Harbin Medical University Cancer Hospital","Harbin","Heilongjiang",{"type":56,"coordinates":98},[99,100],126.65,45.75,{"lat":100,"lon":99},[103],{"name":104,"role":41,"phone":105,"phoneExt":12,"email":106},"Yang Zhou, MD","86-0451-85718915","zhouyang094@126.com",{"facility":108,"status":12,"city":109,"state":110,"zip":12,"country":53,"countryCode":54,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Wuhan","Hubei",{"type":56,"coordinates":112},[113,114],114.26667,30.58333,{"lat":114,"lon":113},[117],{"name":118,"role":41,"phone":119,"phoneExt":12,"email":120},"Fan Yang, MD","86-0278-5726309","fyang@hust.edu.cn",{"facility":122,"status":12,"city":123,"state":124,"zip":12,"country":53,"countryCode":54,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"China-Japan Union Hospital, Jilin University","Changchun","Jilin",{"type":56,"coordinates":126},[127,128],125.32278,43.88,{"lat":128,"lon":127},[131],{"name":132,"role":41,"phone":133,"phoneExt":12,"email":134},"Lin Liu, MD","86-0431-84995684","liulin99@jlu.edu.cn",{"facility":136,"status":12,"city":123,"state":124,"zip":12,"country":53,"countryCode":54,"cosmosGeoPoint":137,"geoPoint":139,"contacts":140},"The Second Hospital of Jilin University",{"type":56,"coordinates":138},[127,128],{"lat":128,"lon":127},[141],{"name":142,"role":41,"phone":143,"phoneExt":12,"email":144},"Jianhua Liu, MD","86-0431-81133827","jian_hua@jlu.edu.cn",{"facility":146,"status":12,"city":147,"state":148,"zip":12,"country":53,"countryCode":54,"cosmosGeoPoint":149,"geoPoint":153,"contacts":154},"Qilu Hospital of Shandong University","Jinan","Shandong",{"type":56,"coordinates":150},[151,152],116.99722,36.66833,{"lat":152,"lon":151},[155],{"name":156,"role":41,"phone":157,"phoneExt":12,"email":158},"Dexin Yu, MD","86-0531-82169336","yudexin0330@sina.com",{"facility":160,"status":12,"city":161,"state":148,"zip":12,"country":53,"countryCode":54,"cosmosGeoPoint":162,"geoPoint":166,"contacts":167},"The Affiliated Hospital of Qingdao University","Qingdao",{"type":56,"coordinates":163},[164,165],120.38042,36.06488,{"lat":165,"lon":164},[168],{"name":169,"role":41,"phone":170,"phoneExt":12,"email":171},"Dapeng Hao, MD","86-0532-82912628","haodp_2009@163.com",{"facility":173,"status":12,"city":174,"state":175,"zip":12,"country":53,"countryCode":54,"cosmosGeoPoint":176,"geoPoint":180,"contacts":181},"The Second Affiliated Hospital of Xi'an Jiaotong University","Xi’an","Shanxi",{"type":56,"coordinates":177},[178,179],113.52486,35.99785,{"lat":179,"lon":178},[182],{"name":183,"role":41,"phone":184,"phoneExt":12,"email":185},"Yuelang Zhang, MD","86-018991232590","18991232590@163.com",{"facility":187,"status":12,"city":188,"state":189,"zip":12,"country":53,"countryCode":54,"cosmosGeoPoint":190,"geoPoint":194,"contacts":195},"Tianjin Second People's Hospital","Tianjin","Tianjin Municipality",{"type":56,"coordinates":191},[192,193],117.17667,39.14222,{"lat":193,"lon":192},[196],{"name":197,"role":41,"phone":198,"phoneExt":12,"email":199},"Shengjuan Yao, MD","86-013821953063","yaoshengjuan8206@163.com",{"facility":201,"status":12,"city":202,"state":203,"zip":12,"country":53,"countryCode":54,"cosmosGeoPoint":204,"geoPoint":208,"contacts":209},"People's Hospital of Xishuangbanna Dai Autonomous Prefecture","Xishuangbanna Dai Autonomous Prefecture","Yunnan",{"type":56,"coordinates":205},[206,207],100.80317,22.00322,{"lat":207,"lon":206},[210],{"name":211,"role":41,"phone":212,"phoneExt":12,"email":213},"Yunhui Yang, MD","86-018908814818","54209535@qq.com",{"type":215,"investigatorFullName":216,"investigatorTitle":217,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"PRINCIPAL_INVESTIGATOR","Wang Yi","Professor",[219],{"name":220,"class":221},"National Research Institute for Family Planning","UNKNOWN","100593757","comparison-of-ultrasound-abbreviated-mri-with-and-without-hbp-as-modalities-for-hcc-surveillance-in-patients-with-high-risk-100593757",false,"NCT07010588","Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk","Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk: a Multi-centers, Randomized Controlled Open-label Trial","SHORT","Inclusion criteria\n\n* According to the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024 Edition) from department of medical administration, nation health commission of the People's Republic of China, with any one of the following high-risk factors for liver cancer: hepatitis B and\u002For C virus infection, excessive alcohol consumption, hepatic steatosis or metabolic dysfunction-associated liver disease, dietary exposure to aflatoxin B1, liver cirrhosis from other causes, or a family history of liver cancer, and an aMAP score (age⁃male⁃albi⁃platelets score) of 60-100 points.\n* Liver disease patients with no evidence of suspected liver cancer in any imaging examination (liver US, contrast-enhanced CT, or contrast-enhanced MRI) within the past six months.\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* History of previous liver cancer diagnosis.\n* Baseline screening at enrollment diagnosed with liver cancer.\n* Child-Pugh score ≥ 10 (class C).\n* History of other malignant tumors.\n* Pregnant or lactating women.\n* Clinically diagnosed severe heart\u002Flung disease or uncontrolled comorbidities, with investigator-judged life expectancy \\\u003C 2 years.\n* Glomerular filtration rate \\\u003C 50 mL\u002Fmin.\n* Inability to undergo (enhanced) MRI due to contraindications or relative contraindications.\n* Poor compliance or unsuitability for the clinical trial as judged by the investigator.","ALL","18 Years","75 Years",{"count":234,"type":235},1389,"ESTIMATED","INTERVENTIONAL",[238],"NA","Active surveillance in high-risk hepatocellular carcinoma (HCC) populations enables early detection of tumors. The currently recommended monitoring protocol involves biannual serum alpha-fetoprotein (AFP) testing combined with liver ultrasound (US) examinations. However, conventional US demonstrates limited sensitivity in detecting early-stage HCC lesions.\n\nMRI demonstrates high sensitivity in monitoring cirrhotic patients, but prolonged scanning time limits its routine clinical application. Several abbreviated MRI protocols have been developed for HCC detection, aiming to reduce acquisition time while improving early-stage HCC diagnostic accuracy.\n\nThe main question this clinical trial aims to answer is:\n\nCan non-contrast abbreviated MRI (NC-AMRI) and enhanced abbreviated MRI (E-AMRI) detect more early-stage HCC lesions compared to US-based screening? Researchers will randomly divide the participants into three groups in a 1:1:1 ratio, with different surveillance strategies, focused on early HCC detection rates.",[241,242,243],"Hepatocellular Carcinoma (HCC)","Magnetic Resonance Imaging (MRI)","Randomized Controlled Trial",[245,246,247],"Hepatocellular carcinoma","magnetic resonance imaging","surveillance","NOT_YET_RECRUITING","2025-05-29",{"date":251,"type":252},"2025-06-08","ACTUAL",{"date":254,"type":235},"2025-06",{"date":256,"type":235},"2030-06",{"name":5,"class":6},12]